China – Healthcare, Regulatory and Reimbursement Landscape

All the vital news, analysis, and commentary curated by our industry experts.

$1995

Buy Report Download FREE Resources

Published: March 31, 2021 Report Code: GDHC0083CHR-ST

Report Overview
Table of Contents
Table
Figures

GlobalData, the industry analysis specialist, has released its latest report “China – Healthcare, Regulatory and Reimbursement Landscape”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

The Chinese pharmaceutical industry was valued at $72.1B in 2012 and grew to $134.6B in 2018. It is expected to reach $300.9B by 2025 at a Compound Annual Growth Rate (CAGR) of 12.2%. The increasing elderly population, expanding social health insurance, and regulatory reforms aimed at innovation and minimizing approval timelines are some of the factors driving the growth of the Chinese pharmaceutical market. China’s medical devices market was valued at $28.66B in 2015, which increased to $35.26B in 2019 at a CAGR of 5.36%. It is expected to grow at a CAGR of 5.90% from 2021 to reach $49.40B in 2025. The China’s 14th Five-Year Plan (2021–2025) and the Made in China (MIC) 2025 initiative are intended to strengthen innovation, develop an efficient domestic supply chain, and transform China into a “manufacturing superpower”.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in China, and includes:

An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Novartis, Sinopharm, Jiangsu Hengrui Medicine, and Beijing Tong Ren Tang

Profiles and SWOT analyses of the major players in the medical device market: Abbott, Medtronic, Roche Diagnostics, Boston Scientific, and Shinva

An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices

Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure

An overview of the opportunities for and challenges to growth in the Chinese healthcare market

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

Develop business strategies by understanding the trends shaping and driving China’s healthcare market

Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact China’s healthcare market in the future

Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

1. Table of Contents

1.1List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights: Facts about the Chinese Healthcare Market

2.3 Key Highlights: Healthcare Startups in China

2.4 Key Events: Chinese Healthcare Timeline, 2015–2021

2.5 Key Events: Facts About the Chinese Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019–2020

2.7 Key Events: Top Completed Deals by Value, 2019–2020

2.8 Country Profile, China, 2020

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, China

3.5 Pharmaceutical Market – Market Segments

3.6 Pharmaceutical Market – Market Segment, Generics, China

3.7 Pharmaceutical Market – Market Segment, Biologics and Biosimilars, China

3.8 Pharmaceutical Market – Market Segment, Over-the-Counter Medicines, China

3.9 Pharmaceutical Market – Market Segment, Traditional Chinese Medicines, China

3.10 Pharmaceutical Market – Market Segment, Cell and Gene Therapy, China

3.11 COVID-19 Epidemiology, China

3.12 COVID-19 Impact and Developments in the Healthcare Market, China

3.13 COVID-19 Clinical Trials Landscape, China

3.14 Major Therapeutic Areas, China

3.15 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, China, 2020–2021

6.2Deal Analysis: Medical Devices Market, China, 2020–2021

7. HealthTech Landscape

7.1 HealthTech Deals Landscape, China

7.2 Key HealthTech Deals, China

7.3 Adoption of Technology in Healthcare, China

7.4 Regulatory Scenario Covering Use of Technology in Healthcare, China

7.5 HealthTech Landscape: Benefits and Risks, China

8. Market Access

8.1 Overview of Healthcare System, China

8.2 Reimbursement Process, China

8.3 Overview of Insurance Providers, China

8.4 Out-of-Pocket Spending and Consumer Price Index, China

8.5 Pricing Policies, China

8.6 Regulatory Landscape, China

8.6.1 Overview of Regulatory Agencies

8.7 Marketing Authorization for Pharmaceutical Products, China

8.8 Marketing Authorization for Generic Drugs, China

8.9 Market Authorization for Medical Devices, China

8.10 Intellectual Property Rights, Patent, China

8.11 Intellectual Property Rights, Trademark, China

8.12 Pharmaceutical Clinical Trials Landscape, China

8.13 Medical Devices Clinical Trials Landscape, China

8.14 Pharmaceutical Advertisement Regulations, China

8.15 Labeling and Packaging Regulations, China

9. Country Healthcare Landscape

9.1 Healthcare Policy Highlights, China

9.2 Healthcare Facilities, China

9.3 Life Expectancy and Immunization Rate, China

9.4 Environmental Health, China

9.5 Healthcare Personnel, China

9.6 Disease Burden, China

9.7 Healthcare Expenditure, China

9.8 Pharmaceutical R&D Expenditure, China

10 Trade Associations, China

11 Trade Fairs, China

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Domestic Companies Dominating Chinese Biosimilar Market, China, 2020

Table 2: NMPA-Approved New Drugs of Local Companies, China, 2020 (Jun’20-Dec’20)

Table 3: NMPA-Approved New Drugs of International Companies, China, 2020 (Aug’20-Dec’20)

Table 4: COVID-19 Indicators (Number of Cases), Global and China, 2020

Table 5: COVID-19 Marketed IVD Products (Oct ‘20 to Jan ‘21), China, 2021

Table 6: COVID-19 IVD Pipeline Products (In Approval Process), China, 2021

Table 7: Top Ten Therapeutic Areas by Morbidity Rate (1/100,000), China, 2019

Table 8: Medical Device Market, China, Major Segments ($M), 2020

Table 9: In Vitro Diagnostics Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2018

Table 10: General Surgery Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 11: Orthopedic Devices Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 12: Cardiovascular Devices Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 13: Wound Care Management Market, China, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 14: Public Insurance Schemes, China, 2020

Table 15:Drug Classification System, China, 2020

Table 16: Medical Devices Classification, China, 2020

Table 17: Trademark Process Timeline, China, 2020

Table 18: Trade Fairs, China, 2020

Figures

Figure 1: Pharmaceutical Market, China, Revenue ($B), 2012–2020

Figure 2: Medical Devices Market, China, Revenue ($B), 2015–2020

Figure 3: Healthcare Startups in China, 2020

Figure 4: Number of Deals (2019–2020)

Figure 5: 2019–2020 Deal Overview by Region

Figure 6: Country Profile, China, 2020

Figure 7: Pharmaceutical Market, China, Revenue ($B), 2011–2018

Figure 8: Pharmaceutical Market, China, Revenue Forecast ($B), 2019–2025

Figure 9: Pharmaceutical Exports ($B), China, 2010–2019

Figure 10: Top Export Partners, China, 2019

Figure 11: Pharmaceutical Imports ($B), China, 2010–2019

Figure 12: Top Import Partners, China, 2019

Figure 13: Pharmaceutical Supply Channel, China, 2019

Figure 14: Pharmaceutical Drug Sales Channel, China, 2019

Figure 15: Supply Channel Prior to 2017, China, 2019

Figure 16: Two Invoice System, China, 2019

Figure 17: Approval of Category 1 Innovative Products, China, 2015-2019

Figure 18: OTC Market, China, Revenue ($B), 2011–2020

Figure 19: OTC Medicines Market, Major Categories ($B), China, 2020

Figure 20: OTC Medicines Market, Major Distribution Channels ($M), China, 2020

Figure 21: Traditional Medicines, Revenue ($B), China, 2011–2020

Figure 22: Traditional Medicines, Per Capita Expenditure ($), China, 2011–2020

Figure 23: COVID-19 (Cases), China, 2020

Figure 24: COVID-19 (Deaths), China, 2020

Figure 25: Timeline of Facts & Control Measures During COVID-19 Epidemic, China, Dec ‘19 – Feb ’20

Figure 26: NMPA-approved Drug Applications Amid COVID-19 Epidemic, China, Q1 2019-Q1 2020

Figure 27: NMPA-approved Drug Applications Amid COVID-19 Epidemic, China, 2020

Figure 28: COVID-19 Clinical Trials Count By Trial Status, China, 2020

Figure 29: COVID-19 Clinical Trials Count By Phase, China, 2020

Figure 30: Top Five COVID-19 Clinical Trials Sponsors By Count, China, 2020

Figure 31: Top Five Therapeutic Areas by Morbidity Rate (%), China, 2019

Figure 32: Medical Device Market, China, Revenue ($B), 2015–2020

Figure 33: Medical Device Market, China, Revenue Forecast ($B), 2021–2025

Figure 34: Medical Device Market, China, Major Segments (%), 2020

Figure 35: In Vitro Diagnostics Market, China, Revenue ($B), 2017–2025

Figure 36: In Vitro Diagnostics Market, China, Market Share of Major Players (%), 2019

Figure 37: General Surgery Market, China, Revenue ($M), 2015–2022

Figure 38: General Surgery Market, China, Market Share of Major Players (%), 2019

Figure 39: Orthopedic Devices Market, China, Revenue ($B), 2017–2025

Figure 40: Orthopedic Devices Market, China, Market Share of Major Players (%), 2019

Figure 41: Cardiovascular Devices Market, China, Revenue ($B), 2017–2025

Figure 42: Cardiovascular Devices Market, China, Market Share of Major Players (%), 2019

Figure 43: Wound Care Management Market, China, Revenue ($B), 2017–2025

Figure 44: Wound Care Management Market, China, Market Share of Major Players (%), 2019

Figure 45: Diagnostic Market, China, Revenue ($B), 2015–2020

Figure 46: Diagnostic Market, China, Revenue ($B), 2021–2025

Figure 47: Medical Devices Market, Revenue ($B) of Major Companies, China, 2019

Figure 48: Deal Value and Deal Count, Pharmaceutical Market, China, 2020–2021

Figure 49: Deal Value and Deal Count Sub-types, Pharmaceutical Market, China, 2020–2021

Figure 50: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, China, 2020–2021

Figure 51: Top Five Therapy Areas by Deal Value ($M), Pharmaceutical Market, China, 2020–2021

Figure 52: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, China, 2020–2021

Figure 53: Venture Financing Deals by Quarter, Pharmaceutical Market,

China, 2020–2021 (by value and by number)

Figure 54: Private Equity Deals by Quarter, Pharmaceutical Market,

China, 2020–2021 (by value and by number)

Figure 55: Deal Value and Deal Count, Medical Devices Market,

China, 2020–2021

Figure 56: Deal Value and Deal Count Sub-types, Medical Devices Market,

China, 2020–2021

Figure 57: Deal Value and Deal Count, Quarterly, Medical Devices Market,

China, 2020–2021

Figure 58: Top Equipment Sectors by Deal Value, Medical Devices Market, China, 2020–2021

Figure 59: Top Equipment Sectors by Deal Count, Medical Devices Market, China, 2020–2021

Figure 60: Venture Financing Deals by Quarter, Medical Devices Market, China, 2020–2021 (by value and by number)

Figure 61: Deal Value ($B), HealthTech, China, 2019–2021

Figure 62: Deal Count, HealthTech, China, 2019–2021

Figure 63: Organization of Healthcare System, China, 2020

Figure 64: National Reimbursement Drug List Process, China, 2020

Figure 65: National Reimbursement Drug List Classification, China, 2020

Figure 66: Total Revenue Share of Social Insurance Fund (%), China, 2012-2019

Figure 67: Revenue and Expenditure of Basic Medical Insurance ($), China, 2014–2019

Figure 68: Percentage Revenue Share of Various Social Insurance Funds, China, 2019

Figure 69: OOP Expenditure (% of total expenditure on health), China, 2012–2020

Figure 70: Annual Rate of Change (%), Health Price Index, China, 2012–2019

Figure 71: Pricing Policies, China, 2020

Figure 72: Drug Movement from Market Authorization to Patient Use, China, 2019

Figure 73: Ministry of Food and Drug Safety, Organization Chart, 2020

Figure 74: Center for Drug Evaluation Organization Chart, China, 2019

Figure 75: Timeline for CFDA Reforms, China, 2017–2021

Figure 76: Drug Approval Process, China, 2020

Figure 77: Generic Drug Approval Process, China, 2020

Figure 78: Medical Device Approval Process, China, 2020

Figure 79: Patent Approval Process, China, 2020

Figure 80: Patent Approval Procedure, China, 2020

Figure 81: Trademark Process, China, 2020

Figure 82: Pharmaceutical Clinical Trials Count By Trial Status, China, 2019–2020

Figure 83: Pharmaceutical Clinical Trials Count By Phase, China, 2019–2020

Figure 84: Pharmaceutical Clinical Trials Count By Indication, China, 2019–2020

Figure 85: Top Five Pharmaceutical Clinical Trials Sponsors By Count, China, 2019–2020

Figure 86: Medical Devices Clinical Trials Count by Trial Status, China, 2019–2020

Figure 87: Medical Devices Clinical Trials Count by Indication, China, 2019–2020

Figure 88: Medical Devices Clinical Trials Count by Category, China, 2019–2020

Figure 89: Documents for Advertising Application, China, 2020

Figure 90: Advertising Application Approval Process, China, 2020

Figure 91: Label/Insert Sheet Information, China, 2020

Figure 92: Healthcare Policies, China

Figure 93: Healthy China 2030, Strategic Goals

Figure 94: Number of Hospitals (‘00), China, 2012–2020

Figure 95: Number of Diagnostic Equipment, China, 2012–2020

Figure 96: Number of General and Specialized Hospitals (‘00), China, 2012–2020

Figure 97: Number of Traditional Chinese Medicine Hospitals (‘00), China, 2012–2020

Figure 98: Total Hospital Beds in Medical Institutions (per 1,000 population), China, 2012–2020

Figure 99: Urban Medical Institution Beds (per 1,000 population), China, 2012–2020

Figure 100: Rural Medical Institution Beds (per 1,000 population), China, 2012–2020

Figure 101: Life Expectancy at Birth (Years), China, 2012–2020

Figure 102: Immunization Rate (%), China, 2012–2019

Figure 103: PM2.5 (µg per m3), China, 2012–2019

Figure 104: CO2 Emissions (Billion Tons), China, 2012–2019

Figure 105: Major Causes of Mortality (per 1,000 population), China, 2016

Figure 106: Major Causes of Male Mortality (per 1,000 population), China, 2016

Figure 107: Major Causes of Female Mortality (per 1,000 population), China, 2016

Figure 108: Disability-Adjusted Life Years by Major Disease (per 1,000 population), China, 2016

Figure 109: Healthcare Expenditure as Percentage of GDP (%), China, 2012–2020

Figure 110: Health Expenditure Share (%), China, 2012–2020

Figure 111: Pharmaceutical Expenditure on R&D ($B), China, 2012–2019

Figure 112: Total R&D Expenditure on Manufacturing of Medicines ($B), China, 2012–2019

Frequently asked questions

China – Healthcare, Regulatory and Reimbursement Landscape standard reports

Currency USD

Single User

$1,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

China – Healthcare, Regulatory and Reimbursement Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports

Pharmaceuticals

New

Rare Diseases: Innovation, Investment, and Unmet Needs - Strategic Intelligence

Pharmaceuticals

New

Bio/Pharmaceutical Outsourcing Report, August 2026

Pharmaceuticals

New

Small-Cell Lung Cancer (SCLC): Market View, Current and Future Competitive…

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at China – Healthcare, Regulatory and Reimbursement Landscape in real time.

Access a live China – Healthcare, Regulatory and Reimbursement Landscape dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

China – Healthcare, Regulatory and Reimbursement Landscape

Scope

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports